Anticipitated and Surprising Effect of IL-17-producing CD4+ T Cells on Chronic Graft-Versus-Host Disease after Unmanipulated Allogeneic Blood and Marrow Transplantation (126.17)

Xiang-Yu Zhao,Ling-Ling Xu,Meng Lv,Lan-Ping Xu,Dai-Hong Liu,Kai-Yan Liu,Xiao-Jun Huang
DOI: https://doi.org/10.4049/jimmunol.188.supp.126.17
2012-01-01
The Journal of Immunology
Abstract:The aim of this study was to investigate the effects of Th17 cells on chronic graft-versus-host disease (cGVHD) in patients who had undergone allogeneic transplantation. Allograft from 41 patients were analyzed for Th17 with respect to cGVHD. Seven patients with cGVHD onset and after those achieved complete remission (CR) were monitored for the Th17 in the peripheral blood (PB). RNA was isolated from PB mononuclear cells to detect the transcript levels of STAT5, T-bet, Foxp3 and RORγ. There were significantly differences in Th17 dose in allograft between patients with and without cGVHD (p=0.012), especially with local or pure cGVHD (p=0.001). Patients received a higher Th17 dose in allograft (>1.67×106/kg, p=0.018,n=20) exhibited a higher incidence of cGVHD compared to those received lower Th17 dose (n=21). Th17 cells were highly increased when cGVHD onset and decreased drastically following CR (p=0.018). Patients received a higher Th17 dose exhibited a trend to have the lower incidence of transplantation related mortality (p=0.084) and relapse (p=0.181), and achieved higher incidence of overall survival (p=0.082) and leukemia free survival (p=0.026). No differences in the transcript levels of STAT, T-bet, Foxp3 and RORγwere found between patients with cGVHD onset and after CR. These results suggested that Th17 cells contributed to cGVHD, especially skin cGVHD, and might account for the anti-leukemia effect, therefore increasing the leukemia free survival.
What problem does this paper attempt to address?